Qin S, Chan SL, Gu S, Bai Y, et al. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study. Lancet 2023 Jul 24:S0140-6736(23)00961-3. doi: 10.1016/S0140-6736(23)00961.
PMID: 37499670